生长激素联合醋酸亮丙瑞林治疗特发性中枢性性早熟女童的疗效及安全性分析

Efficacy and safety of growth hormone combined with leuprorelin acetate in treating children with idiopathic central precocious puberty

摘要:

目的 探究生长激素联合醋酸亮丙瑞林治疗特发性中枢性性早熟的疗效及安全性。方法 选取2020年1月—2022年1月贵州省安顺市人民医院收治的90例特发性中枢性性早熟女童，采用随机数字表法分为对照组与研究组，每组45例。对照组采用醋酸亮丙瑞林治疗，研究组采用生长激素联合醋酸亮丙瑞林治疗。收集两组患儿的临床资料，比较治疗前后的性激素［黄体生成素（LH）、卵泡刺激素（FSH）、雌二醇（E₂）］、子宫容积、卵巢容积、血脂［总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）］及空腹血糖（FPG），观察并记录两组患儿的不良反应情况。结果 研究组患儿治疗前后的LH、FSH、E₂、子宫容积、卵巢容积、TC、TG、HDL-C、LDL-C、FPG比较，差异无统计学意义（P >0.05）；研究组女童治疗前后的子宫容积、TC、TG、HDL-C、LDL-C、FPG的差值比较，差异无统计学意义（P >0.05），研究组女童治疗前后的LH、FSH、E₂、卵巢容积的差值高于对照组（P <0.05）。两组不良反应总发生率比较，差异无统计学意义（P >0.05）。结论 生长激素联合醋酸亮丙瑞林治疗特发性中枢性性早熟女童的效果确切，可降低患儿的性激素水平，改善患儿的卵巢容积，安全性好，值得推广。

关键词:特发性中枢性性早熟;生长激素;醋酸亮丙瑞林;性激素;卵巢容积

Abstract:

Objective To explore the efficacy and safety of growth hormone combined with leuprorelin acetate in treating children with idiopathic central precocious puberty (ICPP).Methods From January 2020 to January 2022, 90 children with ICPP accepted by our hospital were collected, the patients were grouped into control group (45 cases, treated with leuprorelin acetate) and study group (45 cases, treated with growth hormone and leuprorelin acetate) by random number table. Clinical data of patients were collected, and sex hormone levels [luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol (E2)], uterine volume, ovarian volume, fasting blood glucose (FPG) and blood lipid levels [total cholesterol (TC), triacylglycerol (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C)] before and after treatment were compared between the two groups were observed, and the occurrence of adverse reactions were recorded in the two groups.Results There were no significant differences in LH, FSH, E2, uterine volume, ovarian volume, FPG, TC, TG, HDL-C, and LDL-C in the study group before and after treatment (P > 0.05). The differences of uterine volume, FPG, TC, TG, HDL-C, and LDL-C in the research group before and after treatment were not statistically significant (P > 0.05), while the differences of LH, FSH, E2, and ovarian volume in the research group before and after treatment were higher than those in the control group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P > 0.05).Conclusion The effect of growth hormone combined with leuprorelin acetate in treating children with ICPP is accurate, which can reduce the level of sex hormone in children, improve the ovarian volume of patients, and is safe and worthy of promotion.

Key words:idiopathic central precocious puberty;growth hormone;leuprorelin acetate;sex hormone;ovarian volume